The FDA has approved long-awaited changes to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) to minimize the burden on patients, prescribers, and pharmacies while protecting safe use of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results